Michelle L. Basil - 15 Sep 2022 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Role
EVP and General Counsel
Signature
/s/ Michelle L. Basil
Issuer symbol
HAE
Transactions as of
15 Sep 2022
Net transactions value
-$1,431,870
Form type
4
Filing time
19 Sep 2022, 16:39:36 UTC
Previous filing
15 Jun 2022
Next filing
21 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HAE Common Stock Options Exercise $428,648 +11,154 +27% $38.43 51,789 15 Sep 2022 Direct F1, F2
transaction HAE Common Stock Options Exercise $592,579 +14,231 +27% $41.64 66,020 15 Sep 2022 Direct F1, F2
transaction HAE Common Stock Options Exercise $179,497 +3,173 +4.8% $56.57 69,193 15 Sep 2022 Direct F1, F2
transaction HAE Common Stock Sale $2,159,317 -27,769 -40% $77.76 41,424 15 Sep 2022 Direct F1, F2, F3
transaction HAE Common Stock Sale $473,276 -6,029 -15% $78.50 35,395 15 Sep 2022 Direct F1, F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HAE Non-qualified Stock Option (Right to Buy) Options Exercise $0 -11,154 -76% $0.000000 3,464 15 Sep 2022 Common Stock 11,154 $38.43 Direct F1, F5
transaction HAE Non-qualified Stock Option (Right to Buy) Options Exercise $0 -14,231 -77% $0.000000 4,213 15 Sep 2022 Common Stock 14,231 $41.64 Direct F1, F5
transaction HAE Non-qualified Stock Option (Right to Buy) Options Exercise $0 -3,173 -19% $0.000000 13,564 15 Sep 2022 Common Stock 3,173 $56.57 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction pursuant to an existing 10b5-1 trading plan.
F2 This number includes unvested restricted stock units ("RSUs") previously reported.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.33 to $78.30, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.33 to $78.85, inclusive.
F5 Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.